(Q28275006)
Statements
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials (English)
0 references
November 2012
0 references
48
0 references
16
0 references
3082-92
0 references